Has anyone independently verified a Homopeptide liraglutide batch COA?

Conditions: Homopeptide · liraglutide.

The claim is plausible, which is exactly why I want to check it.

I am able to read a paper if someone points me at one.

Can anyone point me at a primary source, or confirm that there is not one?

Start from what "research use only" actually means, because most of the downstream questions are answered by it. It means no release testing, no pharmacovigilance, no regulatory obligation to you, and no recourse.

Cost per milligram, worked honestly: a 10 mg vial at £34 is £3.40 per nominal milligram. If the content assay says 9.2 mg, that is £3.70 per actual milligram. If you then lose 4 µL of dead space per draw from a 2 mL fill across twenty draws, that is 80 µL or four per cent of the fill, taking you to £3.85. Add a £110 content assay amortised across the vial and it is £14.85 per milligram for the first vial of a new lot and £3.85 thereafter. The testing dominates, which is the actual argument for buying larger lots.

On declarations: the accurate description of a research reference material is a research reference material, and accuracy is both the legal position and the practical one. A declaration that misdescribes the contents converts a customs question into a different kind of question, and it does so on a document with your name on it.

Independent testing costs have been stable enough over the past two years that amortisation arithmetic across a lot is worth doing before choosing a lot size, and the numbers usually favour a larger lot tested once over several small lots tested never.

Worth being explicit that this site sells nothing, is not affiliated with any supplier, and has no financial relationship with any vendor discussed. Vendor storefronts are linked from the vendor directory, marked nofollow and sponsored.

Assume no recourse and plan accordingly. That assumption is both prudent and, in this context, accurate.

edited 5 Jun 2026 by jo_vandeberg — added a caveat about sampling

The relevant detail is that the question to ask is not whether a vendor is good but what evidence exists, of what kind, about which lots, from whom. Reputation is a compression of that evidence and it compresses badly.

The diagnostic red flags, in rough order of how much they tell you: a certificate whose lot number does not match the vial; a certificate with no method section; a purity figure quoted to two decimal places with no chromatogram; a testing date that precedes the stated manufacturing date; identical certificates across nominally different lots; and "sterile filtered" offered in place of a sterility test. Each of those is a specific inference, not a vibe.

A defensible group-buy structure has three properties: the material is tested before it is split, the test is paid for from the pool rather than by the organiser, and the split is documented with photographs and a per-participant record of lot, volume and date. If any participant can reconstruct what they received from the records, a later dispute is resolvable. If not, it is not.

The economics of pooled purchasing are not specific to this field, and the failure modes documented in the general literature on informal collective purchasing — organiser default, quality dispute without adjudication, and free-riding on testing costs — are exactly the ones that recur here.

I would resist treating a long track record as evidence of current quality. Suppliers change synthesis partners, fill sites and staff, and a 2024 result is weak evidence about a 2026 lot.

Structure the group buy so that no single person is simultaneously the treasurer, the custodian and the arbiter. That one change removes most of the failure modes.

A lane is a physical object with a temperature profile and a customs regime, and choosing one is a real decision rather than a shipping-option checkbox.

Personal-importation discretion varies more than people assume. Several jurisdictions operate a published enforcement-discretion policy for small quantities for personal use of unapproved products; several do not, and treat any importation of an unapproved medicinal product as an offence irrespective of quantity. The distinction is jurisdiction-specific and worth checking rather than inferring from a forum consensus.

Regulatory positions on personal importation are published: the relevant frameworks are the US FDA’s personal importation policy in its Regulatory Procedures Manual, the UK MHRA’s guidance on importing medicines for personal use, and the equivalent national provisions in the EU member states and Australia’s Therapeutic Goods Administration personal importation scheme. They differ materially from each other.

The evidence you want is boring: the same result, from an independent laboratory, across more than one lot, over more than one year.

Evaluate a supplier on the documentation they cannot fabricate cheaply, which in practice means lot-specific certificates from a laboratory that hosts its own reports and a testing history that spans more than one lot.

Lot-to-lot content variation of nine per cent between two nominally identical lots, both within a stated specification, is the single most common finding in independent testing and the least discussed. It is not fraud; it is the consequence of a fill process controlled to a tolerance rather than to a target. It is also the reason a per-lot content assay is worth more than a per-supplier reputation.

The caveat is that none of this makes an unapproved product safe or lawful to use. It reduces one category of uncertainty — what is in the vial — and leaves every other category untouched.

Test the first lot from any new supplier, set your accept threshold before the result arrives, and keep the certificate with the lot number and the date in one place.